CareDx, Inc (NASDAQ:CDNA) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its position in CareDx, Inc (NASDAQ:CDNA) by 2.8% in the third quarter, Holdings Channel reports. The firm owned 499,480 shares of the company’s stock after purchasing an additional 13,547 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in CareDx were worth $15,596,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Royce & Associates LP lifted its holdings in CareDx by 0.3% during the 3rd quarter. Royce & Associates LP now owns 393,286 shares of the company’s stock worth $12,280,000 after buying an additional 1,000 shares during the last quarter. Quest Partners LLC raised its position in shares of CareDx by 37.8% during the 3rd quarter. Quest Partners LLC now owns 5,611 shares of the company’s stock valued at $175,000 after acquiring an additional 1,540 shares in the last quarter. ClariVest Asset Management LLC lifted its stake in CareDx by 2.9% during the second quarter. ClariVest Asset Management LLC now owns 64,027 shares of the company’s stock worth $994,000 after purchasing an additional 1,810 shares during the last quarter. GAMMA Investing LLC boosted its holdings in CareDx by 1,021.8% in the second quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock worth $34,000 after purchasing an additional 2,013 shares during the period. Finally, nVerses Capital LLC increased its stake in CareDx by 175.0% during the third quarter. nVerses Capital LLC now owns 3,300 shares of the company’s stock valued at $103,000 after purchasing an additional 2,100 shares during the last quarter.

Insider Activity

In other news, Director Peter Maag sold 5,000 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the sale, the director now directly owns 330,024 shares of the company’s stock, valued at approximately $8,250,600. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.90% of the stock is currently owned by insiders.

CareDx Stock Performance

Shares of CDNA opened at $25.04 on Friday. The company has a market capitalization of $1.34 billion, a PE ratio of -9.27 and a beta of 1.84. The company’s 50 day moving average price is $25.18 and its 200 day moving average price is $22.90. CareDx, Inc has a 52 week low of $7.42 and a 52 week high of $34.84.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.11. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The company had revenue of $82.88 million during the quarter, compared to the consensus estimate of $80.04 million. During the same period last year, the business earned ($0.43) EPS. The business’s quarterly revenue was up 23.4% on a year-over-year basis. On average, equities analysts forecast that CareDx, Inc will post -0.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CDNA has been the topic of a number of recent research reports. BTIG Research cut their target price on shares of CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, November 5th. HC Wainwright reissued a “neutral” rating on shares of CareDx in a report on Tuesday, October 22nd. StockNews.com upgraded CareDx from a “hold” rating to a “buy” rating in a research report on Thursday, October 17th. The Goldman Sachs Group increased their target price on CareDx from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Finally, Wells Fargo & Company initiated coverage on shares of CareDx in a report on Tuesday, August 27th. They set an “underweight” rating and a $28.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.60.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.